medigraphic.com
ISSN 1527-3172 (Electronic)

2022, Number 3-4

<< Back Next >>

MEDICC Review 2022; 24 (3-4)

Polyserositis as a Post–Covid-19 Complication

Hernández-Perera JC, Piñeiro-Pérez D, Martínez-Muñiz JO, Correa-Padilla JM, de Armas-Fernández MC, Jordán-González JA, Dávila-Gómez CA, Domínguez-Romero A, Contino-López R

Language: English
References: 16
Page: 57-60
PDF size: 232.05 Kb.


ABSTRACT

INTRODUCTION Polyserositis is described as infl ammation with eff usion of more than one serous membrane. There is very little published literature linking it to COVID-19 as a late complication.
OBJECTIVE Present and describe a case of post–COVID-19 polyserositis.
METHODS Data were collected from the medical record of a female patient admitted for fainting spells and marked weakness. The patient underwent a clinical evaluation, additional hematology, imaging and histopathology tests, and a surgical procedure.
RESULTS We present the case of a 57-year-old female patient admitted to hospital for fainting spells and marked weakness, four months after COVID-19 infection. She also had a history of obesity, asthma, type 2 diabetes mellitus and a cholecystectomy in December 1992 for gallstones. Clinical assessment revealed pericardial eff usion and bilateral pleural eff usion, in addition to a tumor-like lesion outside the pericardium, proximal to the right ventricular wall. A surgical procedure and fi ndings from additional tests led to diagnoses of thymic remnants and polyserositis.
CONCLUSIONS This is a case of polyserositis in a post– COVID-19 patient. After other causes of polyserositis were ruled out, and since there is a likely physiological and pathogenic mechanism operating between the two diseases, the polyserositis was determined to be a late complication of COVID-19. To date, it is the second case reported in the world and the first reported in Cuba.


REFERENCES

  1. Himmel M, Frey S. SARS-CoV-2: internationalinvestigation under the WHO or BWC. FrontPublic Health. 2022 Feb 3;9:636679. https://doi.org/10.3389/fpubh.2021.636679

  2. Pillai A, Lawson B. Coronavirus disease 2019and cardiovascular diseases: collateral damage?Curr Opin Anesthesiol. 2022 Feb 1;35(1):5–11.https://doi.org/10.1097/aco.0000000000001076

  3. Oleynick C. Symptoms of pleurisy as the initialpresentation of COVID-19. Am J Case Rep. 2020Jul 24;21:e925775. https://doi.org/10.12659/ajcr.925775

  4. Ucan B, Kaynak Sahap S, Cinar HG, Tasci YildizY, Uner C, Polat M, et al. Multisystem infl ammatorysyndrome in children associated with SARSCoV-2: extracardiac radiological fi ndings. Br JRadiol. 2022 Jan 1;95(1129):20210570. https://doi.org/10.1259/bjr.20210570

  5. Boix V, Merino E. Síndrome post-COVID. Eldesafío continúa [Post-COVID syndrome. Thenever ending challenge]. Med Clin (Barc). 2022 Feb25;158(4):178–80. Epub 2021 Dec 2. https://doi.org/10.1016/j.medcli.2021.10.002. Spanish, English.

  6. Messin L, Puyraveau M, Benabdallah Y, LepillerQ, Gendrin V, Zayet S, et al. COVEVOL:Natural evolution at 6 months of COVID-19.Viruses. 2021 Oct 25;13(11):2151. https://doi.org/10.3390/v13112151

  7. Harris E, Shanghavi S, Viner T. Polyserositissecondary to COVID-19: the diagnostic dilemma.BMJ Case Rep. 2021 Sep 27;14(9):e243880.https://doi.org/10.1136/bcr-2021-243880

  8. Klimek-Piotrowska W, Mizia E, Kużdżał J, LazarA, Lis M, Pankowski J. Ectopic thymic tissue inthe mediastinum: limitations for the operativetreatment of myasthenia gravis†. Eur J CardiothoracSurg. 2012 Jul 1;42(1):61–5. https://doi.org/10.1093/ejcts/ezr268

  9. Losada I, González-Moreno J, Roda N, VentayolL, Borjas Y, Domínguez FJ, et al. Polyserositis:a diagnostic challenge. Intern Med J.2018 Aug;48(8):982–7. https://doi.org/10.1111/imj.13966

  10. Refaat MM, Katz WE. Neoplastic pericardialeff usion. Clin Cardiol. 2011 Oct;34(10):593–8.https://doi.org/10.1002/clc.20936

  11. Wu Y-B, Xu L-L, Wang X-J, Wang Z, Zhang J,Tong Z-H, et al. Diagnostic value of medical thoracoscopyin malignant pleural eff usion. BMCPulm Med. 2017 Aug 4;17(1):109. https://doi.org/10.1186/s12890-017-0451-1

  12. Mizia E, Klimek-Piotrowska W, Kużdżał J, KonopkaT, Lis M, Pankowski J, et al. Residua of thymusin the mediastinum - clinical aspects - cadavericstudy. Folia Med Cracov [Internet]. 2017 [cited2022 Feb 7];LVII(1):23–8. Available at: http://www.fmc.cm-uj.krakow.pl/pdf/57_1_23.pdf

  13. Piccioni A, Brigida M, Loria V, Zanza C,Longhitano Y, Zaccaria R, et al. Role of troponinin COVID-19 pandemic: a review of literature.Eur Rev Med Pharmacol Sci. 2020Oct;24(19):10293–300. https://doi.org/10.26355/eurrev_202010_23254

  14. Rodríguez Y, Novelli L, Rojas M, De Santis M,Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions atthe crossroad of COVID-19. J Autoimmun.2020 Nov;114:102506. https://doi.org/10.1016/j.jaut.2020.102506

  15. Furqan MM, Verma BR, Cremer PC, Imazio M,Klein AL. Pericardial diseases in COVID19: acontemporary review. Curr Cardiol Rep. 2021Jun 3;23(7):90. https://doi.org/10.1007/s11886-021-01519-x

  16. Deftereos SG, Giannopoulos G, Vrachatis DA,Siasos GD, Giotaki SG, Gargalianos P, et al.Eff ect of colchicine vs standard care on cardiacand infl ammatory biomarkers and clinicaloutcomes in patients hospitalized with CoronavirusDisease 2019: the GRECCO-19 randomizedclinical trial. JAMA Netw Open. 2020 Jun1;3(6):e2013136. https://doi.org/10.1001/jamanetworkopen.2020.13136




2020     |     www.medigraphic.com